Lurasidone

Description	Lurasidone is a new atypical antipsychotic. I is also approved for the treatment of depressive episodes associated with bipolar I disorder (bipolar depression) in adults when used alone or in combination with lithium or valproate. Lurasidone acts as an antagonist of the following sites: α1-adrenergic receptor (Ki = 48 nM); α2A-adrenergic receptor (Ki = 1.6 nM); α2C-adrenergic receptor (Ki = 10.8 nM); D1 receptor (Ki = 262 nM); D2 receptor (Ki = 1.7 nM); 5-HT2A receptor (Ki = 2.0 nM); 5-HT2C receptor (Ki = 415 nM); 5-HT7 receptor (Ki = 0.5 nM). And as a partial agonist of the following sites: 5-HT1A receptor (Ki = 6.8 nM). (Source: http://en.wikipedia.org/wiki/Lurasidone).
Pathways	Neuro Signaling Pathway GPCR/G Protein
Targets	5 HT Receptor/Serotonin Receptor Dopamine Receptor

Part data of this page collected from the open network resources, so Biochempartner can not guarantee its accuracy.

For product details of different batches, please contact our Customer

Products are for research use only and not for human use. We do not sell to patients.